Employing multiple models, methods and mechanisms in bipolar disorder research

Biochemical Society Transactions

Volumn 37, Issue 5, 2009, Pages 1077-1079

  Williams, Robin S B ^a  

^a UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Bipolar disorder; Glycogen synthase kinase 3 (GSK3); Inositol depletion theory; Lithium; Valproic acid

Indexed keywords

CARBAMAZEPINE; GLYCOGEN SYNTHASE KINASE 3; LAMOTRIGINE; LITHIUM SALT; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHOLIPASE A2; VALPROIC ACID;

BIPOLAR DISORDER; CONFERENCE PAPER; DRUG MECHANISM; HEREDITY; HUMAN; MOOD DISORDER; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

AFFECT; ANIMALS; BIPOLAR DISORDER; CONGRESSES AS TOPIC; HUMANS; MODELS, THEORETICAL;

EID: 70350146936     PISSN: 03005127     EISSN: 14708752     Source Type: Journal    
DOI: 10.1042/BST0371077     Document Type: Conference Paper

References (37)

1. Calabrese, J.R. (2008) Overview of patient care issues and treatment in bipolar spectrum and bipolar II disorder. J. Clin. Psychiatry 69, e18
2. Craddock, N. and Sklar, P. (2009) Genetics of bipolar disorder: successful start to a long journey. Trends Genet. 25, 99-105
3. Fajutrao, L., Locklear, J., Priaulx, J. and Heyes, A. (2009) A systematic review of the evidence of the burden of bipolar disorder in Europe. Clin. Pract. Epidemol. Ment. Health 5, 3
4. a World Health Organization (2004) World Health Report 2004: Changing History, WHO, Geneva
5. Goetzel, R.Z., Hawkins, K., Ozminkowski, R.J. and Wang, S. (2003) The health and productivity cost burden of the "top 10" physical and mental health conditions affecting six large U.S. employers in 1999. J. Occup. Environ. Med. 45, 5-14
6. Moreno, C., Laje, G., Blanco, C., Jiang, H., Schmidt, A.B. and Olfson, M. (2007) National trends in the outpatient diagnosis and treatment of bipolar disorder in youth. Arch. Gen. Psychiatry 64, 1032-1039
7. Flaisher-Grinberg, S., Kronfeld-Schor, N. and Einat, H. (2008) Models of mania: from facets to domains and from animal models to model animals. J. Psychopharmacol., doi:10.1177/0269881108097905
8. Quilter, C.R., Gilbert, C.L., Oliver, G.L., Jafer, O., Furlong, R.A., Blott, S.C., Wilson, A.E., Sargent, C.A., Mileham, A. and Affara, N.A. (2008) Gene expression pro.ling in porcine maternal infanticide: a model for puerperal psychosis. Am. J. Med. Genet. B Neuropsychiatr. Genet. 147B, 1126-1137
9. Williams, R.S., Boeckeler, K., Gräf, R., Müller-Taubenberger, A., Li, Z., Isberg, R.R., Wessels, D., Soll, D.R., Alexander, H. and Alexander, S. (2006) Towards a molecular understanding of human diseases using Dictyostelium discoideum. Trends Mol. Med. 12, 415-424
10. 3 and inositol depletion as a cellular target of mood stabilizers. Biochem. Soc. Trans. 37, 1110-1114
11. Kleineidam, A., Vavassori, S., Wang, K., Schweizer, L.M., Griac, P. and Schweizer, M. (2009) Valproic acid- and lithium-sensitivity in prs mutants of Saccharomyces cerevisiae. Biochem. Soc. Trans. 37, 1115-1120
12. Williams, R.S.B., Cheng, L., Mudge, A.W. and Harwood, A.J. (2002) A common mechanism of action for three mood-stabilizing drugs. Nature 417, 292-295
13. Bellani, M., Yeh, P.-H., Tansella, M., Balestrieri, M., Soares, J.C. and Brambilla, P. (2009) DTI studies of corpus callosum in bipolar disorder. Biochem. Soc. Trans. 37, 1096-1098
14. Quraishi, S. and Frangou, S. (2002) Neuropsychology of bipolar disorder: a review. J. Affect. Disord. 72, 209-226
15. Frangou, S. (2009) Risk and resilience in bipolar disorder: rationale and design of the Vulnerability to Bipolar Disorders Study (VIBES). Biochem. Soc. Trans. 37, 1085-1089
16. Breen, G., Harwood, A.J., Gregory, K., Sinclair, M., Collier, D., St Clair, D. and Williams, R.S. (2004) Two peptidase activities decrease in treated bipolar disorder not schizophrenic patients. Bipolar Disord. 6, 156-161
17. Huang, J.T., Leweke, F.M., Oxley, D., Wang, L., Harris, N., Koethe, D., Gerth, C.W., Nolden, B.M., Gross, S., Schreiber, D. et al. (2006) Disease biomarkers in cerebrospinal fluid of patients with first-onset psychosis. PLoS Med. 3, e428
18. Cade, J.F. (1949) Lithium salts in the treatment of psychotic excitement. Med. J. Aust. 36, 349-352
19. Berridge, M.J., Downes, C.P. and Hanley, M.R. (1989) Neural and developmental actions of lithium: a unifying hypothesis. Cell 59, 411-419
20. Agam, G., Bersudsky, Y., Berry, G., Moechars, D., Lavi-Avnon, Y. and Belmaker, R.H. (2009) Knockout mice in understanding the mechanism of action of lithium. Biochem. Soc. Trans. 37, 1121-1125
21. King, J.S., Teo, R., Ryves, J., Reddy, J.V., Peters, O., Orabi, B., Hoeller, O., Williams, R.S. and Harwood, A.J. (2009) The mood stabiliser lithium suppresses PIP3 signalling in Dictyostelium and human cells. Dis. Models Mech. 2, 306-312
22. Xu, X., Müller-Taubenberger, A., Adley, K.E., Pawolleck, N., Lee, V.W., Wiedemann, C., Sihra, T.S., Maniak, M., Jin, T. and Williams, R.S. (2007) Attenuation of phospholipid signaling provides a novel mechanism for the action of valproic acid. Eukaryotic Cell 6, 899-906
23. Deranieh, R.M. and Greenberg, M.L. (2009) Cellular consequences of inositol depletion. Biochem. Soc. Trans. 37, 1099-1103
24. +myo-inositol transporter (HMIT) as a neuronal regulator of phosphoinositide signalling. Biochem. Soc. Trans. 37, 1139-1143
25. Eickholt, B.J., Towers, G.J., Ryves, W.J., Eikel, D., Adley, K., Ylinen, L.M., Chadborn, N.H., Harwood, A.J., Nau, H. and Williams, R.S. (2005) Effects of valproic acid derivatives on inositol trisphosphate depletion, teratogenicity, glycogen synthase kinase-3β inhibition, and viral replication: a screening approach for new bipolar disorder drugs derived from the valproic acid core structure. Mol. Pharmacol. 67, 1426-1433
26. Shimshoni, J.A., Dalton, E.C., Jenkins, A., Eyal, S., Ewan, K., Williams, R.S., Pessah, N., Yagen, B., Harwood, A.J. and Bialer, M. (2007) The effects of central nervous system-active valproic acid constitutional isomers, cyclopropyl analogs, and amide derivatives on neuronal growth cone behavior. Mol. Pharmacol. 71, 884-892
27. Terbach, N. and Williams, R.S.B. (2009) Structure-function studies for the panacea, valproic acid. Biochem. Soc. Trans. 37, 1126-1132
28. O'Brien, W.T. and Klein, P.S. (2009) Validating GSK3 as an in vivo target of lithium action. Biochem. Soc. Trans. 37, 1133-1138
29. Klein, P.S. and Melton, D.A. (1996) A molecular mechanism for the effect of lithium on development. Proc. Natl. Acad. Sci. U.S.A. 93, 8455-8459
30. O'Brien, W.T., Harper, A.D., Jové, F., Woodgett, J.R., Maretto, S., Piccolo, S. and Klein, P.S. (2004) Glycogen synthase kinase-3β haploinsufficiency mimics the behavioral and molecular effects of lithium. J. Neurosci. 24, 6791-6798
31. Gould, T.D., Picchini, A.M., Einat, H. and Manji, H.K. (2006) Targeting glycogen synthase kinase-3 in the CNS: implications for the development of new treatments for mood disorders. Curr. Drug Targets. 7, 1399-1409
32. Gould, T.D., Einat, H., O'Donnell, K.C., Picchini, A.M., Schloesser, R.J. and Manji, H.K. (2007) β-Catenin overexpression in the mouse brain phenocopies lithium-sensitive behaviors. Neuropsychopharmacology 32, 2173-2183
33. Chen, G., Huang, L.D., Jiang, Y.M. and Manji, H.K. (1999) The moodstabilizing agent valproate inhibits the activity of glycogen synthase kinase-3. J. Neurochem. 72, 1327-1330
34. Ryves, W.J., Dalton, E., Harwood, A. and Williams, R. (2005) GSK-3 activity in neocortical cells is inhibited by lithium but not carbamazepine or valproic acid. Bipolar Disord. 7, 260-265
35. Chang, M.C., Contreras, M.A., Rosenberger, T.A., Rintala, J.J., Bell, J.M. and Rapoport, S.I. (2001) Chronic valproate treatment decreases the in vivo turnover of arachidonic acid in brain phospholipids: a possible common effect of mood stabilizers. J. Neurochem. 77, 796-803
36. Chen, G. and Manji, H.K. (2006) The extracellular signal-regulated kinase pathway: an emerging promising target for mood stabilizers. Curr. Opin. Psychiatry 19, 313-323
37. Large, C.H., Di Daniel, E., Li, X. and George, M.S. (2009) Neural network dysfunction in bipolar depression: clues from the efficacy of lamotrigine. Biochem. Soc. Trans. 37, 1080-1084